Beyond their established role in the treatment of T2DM and obesity, GLP-1 RAs are increasingly being investigated for their therapeutic potential in a broad spectrum of metabolic diseases due to their pleiotropic actions, which affect glucose and lipid regulation, inflammation, and organ function. This evidence concerns the gene GLP1R and Obesity.